Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Hard enpoints needed for antidiabeticdrug trials.

November 21, 2008

Analysis of:Study: Diabetes drug fails to slow artery buildup | ap.google.com

Reduction of the intima media thickness is only a surrogate endpoint with little bearing on CVD, stroke and death. The number of different treatment options for pharmacological intervention of type 2 diabetics are groving rapidly. Many of the available oral antidiabeticdrugs and injectable glucoselowering drugs show good efficacy regarding the glucose control. Litte is known about the longterm effects, albeit some recent studies have been outcome studies (ACCORD, VADT, ADVANCE). We need to further understand and learn how to better individualize the treatment of diabetes type 2 in order not to only reduce the glucose levels or bloodpressure or lipids but to give safe and effective treatment resulting in fewer diabetic complications. The bottom line for the patients is not a good Ac1 level but a good life.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS